Vertex Built The NaV1.8 Market, Latigo Stock May Be One To Profit From It (NASDAQ:LTGO)
· seekingalpha.com
Latigo Biotherapeutics (LTGO) looks undervalued post-IPO, with onzotrigine’s Phase 3 pain trial as key catalyst.
Investors are missing the message from this newly listed biotech, Latigo Biotherapeutics ( LTGO ). So far since the August listing, Latigo has been viewed by ma...